Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS.

Trial Profile

Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2012

At a glance

  • Drugs PR1 peptide vaccine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 11 May 2009 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov (NCT00893997), due to slow accrual rates.
    • 11 May 2009 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov (NCT00893997), due to slow accrual rates.
    • 05 May 2009 New source identified and integrated (NCT00893997).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top